Transcriptomics

Dataset Information

0

Expression data from the rituximab-resistant lymphoma cell lines and the parental cell lines


ABSTRACT: Rituximab, a monoclonal antibody against CD20, has achieved great success in the treatment of B cell lymphoma, but many patients have shown resistance to it and led to disease progression eventually. At present, the mechanism of resistance is still not clear, but we consider that it may involve the multiple genes and multiple signaling pathways. Therefore, our study aimed at searching differentially expressed genes of rituximab resistant cell lines (RRCL) by cDNA microarray, and exploring the resistant mechanism of RRCL by using the subsequent bioinformatics methods. In this study, we successfully identified seventy up-regulated genes and forty-two down-regulated genes in both two RRCL. We also isolated the MAPK signaling pathway, which was the significantly enriched pathway in resistant mechanism, through KEGG pathway analysis. Moreover, we discovered the biological behaviors of RRCL that mainly inhibit apoptosis, promote cellular proliferation, transcription and angiogenesis through Gene Ontology (GO) terms analysis. In conclusion, our results suggested that the most closely related pathway to rituximab resistance was MAPK signaling pathway, which may partly be related to its inhibiting the apoptosis of cells and promoting the proliferation of cells and vascular development.

ORGANISM(S): Homo sapiens

PROVIDER: GSE60327 | GEO | 2014/08/13

SECONDARY ACCESSION(S): PRJNA258040

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2014-08-13 | E-GEOD-60327 | biostudies-arrayexpress
2021-01-03 | GSE159852 | GEO
2013-03-12 | E-GEOD-45018 | biostudies-arrayexpress
2013-03-12 | GSE45018 | GEO
2010-10-19 | GSE24742 | GEO
2019-02-13 | GSE112592 | GEO
2021-01-21 | GSE162658 | GEO
2013-06-01 | E-GEOD-46873 | biostudies-arrayexpress
2024-12-17 | GSE273358 | GEO
2024-12-17 | GSE273175 | GEO